JPRN-jRCT2080223304未知2 期
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)-I4V-MC-JAHH
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Have received a diagnosis of SLE at least 24 weeks prior to screening, meeting the American College of Rheumatology (ACR) 1982 revised criteria OR the 2012 Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria.
- •Have a positive antinuclear antibody (ANA) and/or a positive anti-double-stranded deoxyribonucleic acid (dsDNA) as assessed by a central laboratory at screening.
- •Have a SLEDAI-2K score 4 or more based on clinical symptoms (not including lab values) at randomization.
- •Have active arthritis and/or active rash as defined by the SLEDAI-2K at randomization.
排除标准
- •Have active severe lupus nephritis.
- •Have active severe central nervous system (CNS) lupus.
- •Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data.
- •Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection.
- •Are currently receiving oral corticosteroids at doses >20-milligrams per day of prednisone (or equivalent) or have adjusted the dose of corticosteroids within 2 weeks of planned randomization.
- •Have started treatment with or adjusted the dose of nonsteroidal anti-inflammatory drugs (NSAIDs) (for which the NSAID use is intended for treatment of signs and symptoms of SLE) within 4 weeks of planned randomization.
- •Have started treatment with or adjusted the dose of an antimalarial within 12 weeks of planned randomization.
- •Have started treatment with or adjusted the dose of an immunosuppressant within 12 weeks of planned randomization.
- •Have received cyclophosphamide (or any other cytotoxic agent) within 12 weeks prior to screening.
研究者
相似试验
招募中
3 期
Evaluation of therapeutic effect of baricitinib in patients with severe pneumonia requiring non-invasive ventilation induced to Covid 19Acute viral infection caused by the corona virus (COVID-19).COVID-19, virus identifiedU07.1IRCT20220508054780N1Mashhad University of Medical Sciences15
已完成
3 期
A Study in Moderate to Severe Rheumatoid Arthritis ParticipantsRheumatoid ArthritisNCT01721057Eli Lilly and Company684
尚未招募
3 期
studing the therapeutic effect of baricitinib and its side effects in LPP (Lichen Plano Pilaris)lichen planopilaris.Chapter XII Diseases of the skin and subcutaneous tissue(L00-L99)IRCT20221101056374N1Tehran University of Medical Sciences22
进行中（未招募）
2 期
Phase II proof of concept study of baricitinib in individuals who are considered at risk of developing inflammatory arthritis: ExISTInflammatory arthritisMusculoskeletal DiseasesISRCTN53678960niversity of Leeds58
已完成
3 期
A Study in Participants With Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT01711359Eli Lilly and Company588